{"gene":"TFPI2","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1977,"finding":"Placental protein PP5 (later identified as TFPI2) was isolated from human term placenta and characterized as a glycoprotein (MW ~36,600 Da) with serine proteinase-inhibiting activity, capable of inhibiting trypsin and plasmin.","method":"Immunoadsorbent purification, ultracentrifugation, electrophoresis, enzymatic inhibition assays","journal":"Archiv fur Gynakologie","confidence":"Medium","confidence_rationale":"Tier 1 — direct in vitro enzymatic inhibition assay with purified protein; single lab, foundational biochemical characterization","pmids":["579296"],"is_preprint":false},{"year":1985,"finding":"PP5/TFPI2 inhibits thrombin-induced coagulation of fibrinogen in a dose-dependent manner, similar to antithrombin III, but without heparin-cofactor activity; PP5 binds heparin but heparin does not accelerate its inhibitory effect.","method":"In vitro fibrinogen coagulation assay, heparin-binding assay","journal":"Archives of gynecology","confidence":"Medium","confidence_rationale":"Tier 1 — direct in vitro enzymatic assay; single lab, single study","pmids":["4026390"],"is_preprint":false},{"year":1998,"finding":"PP5/TFPI2 mRNA is specifically expressed in syncytiotrophoblasts of human placenta at all gestational periods examined, with no or little expression in choriocarcinoma cell lines, indicating syncytiotrophoblasts as the principal production site.","method":"In situ hybridization, Northern blot analysis","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization by in situ hybridization with functional context; single lab","pmids":["9548189"],"is_preprint":false},{"year":2003,"finding":"Hypermethylation of the TFPI-2 CpG island promoter silences TFPI-2 transcription in JAR choriocarcinoma cells; in vitro methylation of TFPI-2/luciferase promoter constructs confirmed methylation-dependent transcriptional silencing.","method":"5'-aza-2'-deoxycytidine demethylation, luciferase reporter assay, bisulfite genomic sequencing","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter assay with orthogonal methods; single lab","pmids":["12956419"],"is_preprint":false},{"year":2005,"finding":"Restored expression of TFPI-2 in pancreatic cancer cells (which have epigenetically silenced TFPI-2) suppresses proliferation, migration, and invasive potential in vitro, establishing TFPI-2 as a functional tumor suppressor through inhibition of extracellular matrix degradation.","method":"Stable transfection/re-expression, proliferation assay, migration assay, invasion assay, methylation-specific PCR, microarray","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays with loss-of-function and re-expression; moderate evidence","pmids":["15592528"],"is_preprint":false},{"year":2007,"finding":"A novel aberrantly-spliced TFPI-2 (asTFPI-2) transcript lacking 5'-UTR and poly(A)+ tail is expressed 4- to 50-fold more in tumor cells than normal cells, representing an additional mechanism by which tumor cells downregulate functional TFPI-2 protein to enhance extracellular matrix degradation.","method":"RT-PCR, 5'- and 3'-RACE, quantitative real-time RT-PCR, nucleotide sequence analysis","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 — direct molecular characterization of splice variant with quantitative expression analysis; single lab","pmids":["17352822"],"is_preprint":false},{"year":2011,"finding":"Lentiviral knockdown of TFPI-2 in glioma cell lines significantly increased cell proliferation, migration, and invasion; the anti-invasive properties of TFPI-2 were associated with inhibition of MMP-1 and MMP-2 activity.","method":"Lentiviral shRNA knockdown, proliferation assay, migration assay, invasion assay, MMP inhibitor experiments","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD with specific phenotypic readout and pathway placement via MMP inhibitors; single lab","pmids":["21530612"],"is_preprint":false},{"year":2013,"finding":"The TFPI-2 derived C-terminal peptide EDC34 exerts direct bactericidal effects, boosts activation of the classical complement pathway including formation of antimicrobial C3a, and inhibits bacteria-induced activation of the contact/coagulation system.","method":"In vitro bactericidal assay, complement activation assay, mouse infection models (E. coli, P. aeruginosa)","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1–2 — multiple in vitro and in vivo mechanistic assays with defined functional readouts; single lab but multiple orthogonal methods","pmids":["24339780"],"is_preprint":false},{"year":2013,"finding":"TFPI2 is specifically secreted by ovarian clear cell adenocarcinoma (CCA) cell lines and detected at elevated levels in patient sera, identified via mass spectrometry of conditioned media as a biomarker distinguishing CCA from other epithelial ovarian cancer subtypes.","method":"Mass spectrometry of conditioned media, RT-PCR, Western blot, ELISA","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 2 — secretome-based identification with orthogonal validation; single lab","pmids":["23805888"],"is_preprint":false},{"year":2018,"finding":"lncRNA AC003092.1 regulates TFPI-2 expression through miR-195 by acting as a competing endogenous RNA (ceRNA), increasing TFPI-2 levels and promoting TMZ-induced apoptosis in glioblastoma cells.","method":"qRT-PCR, ceRNA/miRNA luciferase reporter assay, overexpression/knockdown, in vitro and in vivo functional assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — ceRNA mechanism with luciferase validation and functional rescue; single lab","pmids":["30442884"],"is_preprint":false},{"year":2018,"finding":"lncRNA linc00473 inhibits TFPI2 transcription in trophoblast cells through binding to LSD1 (lysine-specific demethylase 1), thereby suppressing TFPI2 expression and affecting trophoblast proliferation and apoptosis.","method":"RNA-seq, qRT-PCR, RNA immunoprecipitation, siRNA knockdown, overexpression","journal":"Molecular therapy. Nucleic acids","confidence":"Medium","confidence_rationale":"Tier 2 — direct RNA-protein interaction with functional readout; single lab","pmids":["30195776"],"is_preprint":false},{"year":2019,"finding":"lncRNA AGAP2-AS1 interacts with EZH2 and LSD1 and recruits them to the TFPI2 promoter to suppress TFPI2 transcription, promoting glioblastoma cell proliferation and invasion; TFPI2 overexpression reversed AGAP2-AS1-driven oncogenic effects.","method":"RNA immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP), overexpression/knockdown, in vitro and in vivo functional assays","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 — RIP and ChIP with functional rescue; single lab","pmids":["31186379"],"is_preprint":false},{"year":2019,"finding":"Mono-ADP-ribosylation of histone H3R117 suppresses TET1 expression and reduces TET1 affinity for the TFPI2 promoter (via H3K9me3 enrichment), thereby impairing demethylation and maintaining hypermethylation of the TFPI2 promoter in colorectal cancer cells.","method":"Chromatin immunoprecipitation, bisulfite sequencing, TET1 knockout, H3R117A mutation, ATAC-seq, DNA methylation analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 — multiple epigenetic assays with genetic manipulation and direct mechanistic pathway from H3R117 modification to TFPI2 methylation; single lab with multiple orthogonal methods","pmids":["30651599"],"is_preprint":false},{"year":2020,"finding":"TFPI2 suppresses breast cancer cell proliferation, migration, and invasion through inhibiting TWIST1 expression; TWIST1 in turn upregulates integrin α5, and TFPI2 overexpression suppresses tumor growth in vivo via the TWIST1-integrin α5 axis.","method":"CCK8 assay, colony formation, wound healing, transwell invasion, Western blot, in vivo xenograft model, immunohistochemistry","journal":"Molecular medicine (Cambridge, Mass.)","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays with pathway placement (TWIST1-integrin α5) and in vivo validation; single lab","pmids":["32248791"],"is_preprint":false},{"year":2022,"finding":"MBD3 inhibits TFPI2 transcription via the NuRD complex-mediated deacetylation, reactivating MMP activity and PI3K/AKT signaling, thereby promoting hepatocellular carcinoma growth and metastasis.","method":"ChIP, immunoprecipitation, siRNA knockdown, overexpression, in vitro and in vivo functional assays, immunohistochemistry","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and co-IP establishing NuRD complex-mediated epigenetic silencing of TFPI2 with functional consequences; single lab","pmids":["35501390"],"is_preprint":false},{"year":2022,"finding":"TFPI2 promotes TGF-β2/Smad signaling-driven endothelial-mesenchymal transition in diabetic nephropathy by interfering with the interaction between SMURF2 and SMAD7, preventing SMAD7-mediated inhibition of the TGF-β2 pathway.","method":"Co-immunoprecipitation, AAV-mediated shRNA knockdown in vivo, overexpression in human renal glomerular endothelial cells, high-glucose treatment, EndMT marker analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP establishing protein-protein interaction interference with functional in vitro and in vivo readouts; single lab","pmids":["35157852"],"is_preprint":false},{"year":2023,"finding":"TFPI2 promotes glioblastoma stem cell (GSC) self-renewal and tumor growth via activation of the JNK-STAT3 pathway; secreted TFPI2 binds CD51 on microglia to trigger immunosuppressive polarization through STAT6 signaling; inhibition of the TFPI2-CD51-STAT6 axis activates T cells and synergizes with anti-PD1 therapy.","method":"Receptor identification (CD51), co-immunoprecipitation/binding assays, genetic knockdown/overexpression, STAT3/STAT6 pathway analysis, mouse GBM models with anti-PD1 combination, flow cytometry","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods identifying receptor (CD51), downstream signaling (JNK-STAT3, STAT6), and functional in vivo validation; single lab but rigorous multi-method approach","pmids":["37067051"],"is_preprint":false},{"year":2013,"finding":"TFPI-2 overexpression in small cell lung cancer cells decreased MMP expression (particularly MMP-1 and MMP-3) by downregulating phosphorylation of MAPK signaling pathway proteins, and inhibited tumor growth in an orthotopic mouse model.","method":"Stable overexpression, in vitro viability/apoptosis/cell cycle assays, MMP expression analysis, Western blot (MAPK phosphorylation), orthotopic mouse model","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression with pathway placement (MAPK-MMP) and in vivo validation; single lab","pmids":["23905012"],"is_preprint":false}],"current_model":"TFPI2 (Tissue Factor Pathway Inhibitor 2/Placental Protein 5) is a secreted Kunitz-type serine protease inhibitor that inhibits plasmin, trypsin, thrombin, and MMPs to suppress extracellular matrix degradation; its promoter is frequently silenced by CpG hypermethylation (maintained by H3R117 mono-ADP-ribosylation suppressing TET1, or by lncRNAs recruiting EZH2/LSD1/MBD3-NuRD complexes); when expressed, it suppresses tumor invasion via MMP inhibition, activates apoptosis, restrains the JNK-STAT3 stemness pathway in glioblastoma, and its secreted form engages CD51 on microglia to drive immunosuppressive STAT6 signaling, while a C-terminal peptide (EDC34) exerts bactericidal and complement-activating activities."},"narrative":{"teleology":[{"year":1977,"claim":"Identification of PP5/TFPI2 as a placental glycoprotein with serine proteinase inhibitor activity established the foundational biochemistry of the protein, answering what molecular activity it encodes.","evidence":"Immunoadsorbent purification from human placenta with enzymatic inhibition assays against trypsin and plasmin","pmids":["579296"],"confidence":"Medium","gaps":["Inhibitory mechanism (Kunitz domain involvement) not yet defined","No structural characterization","Range of protease targets unknown"]},{"year":1985,"claim":"Demonstration that PP5/TFPI2 inhibits thrombin-induced fibrinogen coagulation expanded its substrate repertoire to the coagulation cascade and clarified that, unlike antithrombin III, heparin does not serve as a cofactor for its activity.","evidence":"In vitro fibrinogen coagulation assay and heparin-binding assay","pmids":["4026390"],"confidence":"Medium","gaps":["Physiological relevance to hemostasis in vivo not tested","Stoichiometry and kinetics of thrombin inhibition undefined"]},{"year":1998,"claim":"Localization of TFPI2 mRNA specifically to syncytiotrophoblasts across gestation established the cell type responsible for its placental production and noted its loss in choriocarcinoma, foreshadowing its tumor-suppressive role.","evidence":"In situ hybridization and Northern blot on human placental tissue and choriocarcinoma cell lines","pmids":["9548189"],"confidence":"Medium","gaps":["Mechanism of silencing in choriocarcinoma not addressed","Functional role in trophoblast biology not tested"]},{"year":2003,"claim":"Identification of CpG island promoter hypermethylation as the mechanism silencing TFPI2 in choriocarcinoma cells provided the first epigenetic explanation for its loss in cancer.","evidence":"5-aza-2'-deoxycytidine demethylation, methylated luciferase reporter constructs, bisulfite sequencing in JAR cells","pmids":["12956419"],"confidence":"Medium","gaps":["Upstream signals initiating hypermethylation unknown","Generalizability to other tumor types not yet shown"]},{"year":2005,"claim":"Re-expression of TFPI2 in pancreatic cancer cells suppressed proliferation, migration, and invasion, establishing it as a functional tumor suppressor whose loss enables extracellular matrix degradation.","evidence":"Stable transfection/re-expression with proliferation, migration, invasion assays and methylation-specific PCR in pancreatic cancer cell lines","pmids":["15592528"],"confidence":"High","gaps":["Specific protease targets mediating ECM degradation not identified in this system","In vivo tumor suppressor activity not tested"]},{"year":2011,"claim":"Knockdown of TFPI2 in glioma cells increased proliferation and invasion specifically through enhanced MMP-1 and MMP-2 activity, placing MMP inhibition as the proximal mechanism of its anti-invasive function.","evidence":"Lentiviral shRNA knockdown with MMP inhibitor rescue experiments in glioma cell lines","pmids":["21530612"],"confidence":"Medium","gaps":["Whether TFPI2 directly inhibits MMP-1/2 or acts indirectly not resolved","In vivo relevance in glioma not shown in this study"]},{"year":2013,"claim":"TFPI2 overexpression in small cell lung cancer cells revealed that it downregulates MMP-1/3 expression by reducing MAPK pathway phosphorylation and suppresses orthotopic tumor growth, establishing a signaling mechanism upstream of MMP transcription.","evidence":"Stable overexpression, Western blot of MAPK phosphorylation, MMP expression analysis, orthotopic mouse model","pmids":["23905012"],"confidence":"Medium","gaps":["How a secreted protease inhibitor alters intracellular MAPK signaling is unclear","Receptor or membrane target mediating this effect not identified"]},{"year":2013,"claim":"The C-terminal peptide EDC34 derived from TFPI2 was shown to have direct bactericidal activity, to activate the classical complement pathway generating antimicrobial C3a, and to inhibit bacteria-induced contact activation, revealing an innate immune function distinct from its protease inhibitor activity.","evidence":"In vitro bactericidal assays, complement activation assays, mouse infection models with E. coli and P. aeruginosa","pmids":["24339780"],"confidence":"High","gaps":["Whether full-length TFPI2 shares these antimicrobial properties is unclear","Structural basis for complement activation not defined"]},{"year":2019,"claim":"Multiple epigenetic silencing mechanisms converging on the TFPI2 promoter were elucidated: mono-ADP-ribosylation of H3R117 maintains promoter hypermethylation by blocking TET1 access, while lncRNAs recruit EZH2, LSD1, and MBD3-NuRD complexes, collectively explaining the diverse routes to TFPI2 loss in cancer.","evidence":"ChIP, bisulfite sequencing, TET1 KO, H3R117A mutation, ATAC-seq (colorectal cancer); RIP/ChIP with functional rescue (glioblastoma, trophoblast, hepatocellular carcinoma)","pmids":["30651599","31186379","30195776","35501390"],"confidence":"High","gaps":["Relative contribution of each epigenetic pathway in specific tumor types not compared","Whether these mechanisms operate in normal tissue homeostasis unknown"]},{"year":2020,"claim":"TFPI2 was found to suppress breast cancer invasion through downregulation of TWIST1 and its downstream target integrin α5, adding an EMT-linked transcriptional axis to its tumor-suppressive repertoire.","evidence":"Overexpression/knockdown in breast cancer cells, in vivo xenograft, Western blot of TWIST1-integrin α5 axis","pmids":["32248791"],"confidence":"Medium","gaps":["Mechanism by which a secreted protease inhibitor regulates TWIST1 transcription not defined","Direct physical interaction not shown"]},{"year":2022,"claim":"TFPI2 was shown to promote TGF-β2/Smad signaling-driven endothelial-mesenchymal transition in diabetic nephropathy by disrupting the SMURF2-SMAD7 interaction, revealing a context-dependent pro-fibrotic role separate from its tumor-suppressive functions.","evidence":"Co-immunoprecipitation, AAV-mediated shRNA in vivo, overexpression in renal endothelial cells under high glucose","pmids":["35157852"],"confidence":"Medium","gaps":["Whether this SMURF2-SMAD7 disruption occurs via direct binding or protease activity is unknown","Relevance to non-diabetic fibrotic settings not tested"]},{"year":2023,"claim":"Identification of CD51 as the microglial receptor for secreted TFPI2 and delineation of dual signaling—JNK-STAT3 in glioblastoma stem cells promoting self-renewal and STAT6 in microglia driving immunosuppression—provided a receptor-to-phenotype mechanism linking TFPI2 to the tumor immune microenvironment.","evidence":"Receptor identification (CD51), co-IP/binding assays, STAT3/STAT6 pathway analysis, mouse GBM models with anti-PD1 combination, flow cytometry","pmids":["37067051"],"confidence":"High","gaps":["Whether CD51 engagement requires full-length TFPI2 or specific domains is unknown","Generalizability of TFPI2-CD51-STAT6 axis beyond glioblastoma not tested","Structural basis of TFPI2-CD51 interaction not resolved"]},{"year":null,"claim":"How a single secreted Kunitz-type inhibitor exerts such divergent intracellular signaling effects (MAPK, JNK-STAT3, STAT6, TGF-β/Smad) and whether these depend on its protease-inhibitory activity, direct receptor engagement (e.g., CD51), or distinct protein domains remains an open question.","evidence":"","pmids":[],"confidence":"Low","gaps":["Domain-function mapping for signaling versus protease inhibition not performed","No structural model of TFPI2 with receptors or substrates","Relative importance of autocrine versus paracrine roles in the tumor microenvironment unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,6,17]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[16]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,7,8,16]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[1]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,16,17]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[4,6,17]}],"complexes":[],"partners":["CD51","SMURF2","SMAD7","MMP-1","MMP-2"],"other_free_text":[]},"mechanistic_narrative":"TFPI2 is a secreted Kunitz-type serine protease inhibitor that functions as a broad regulator of extracellular proteolysis, hemostasis, innate immunity, and tumor suppression. It directly inhibits trypsin, plasmin, and thrombin, and suppresses MMP-1, MMP-2, and MMP-3 activity through MAPK pathway downregulation, thereby restraining extracellular matrix degradation, cell invasion, and metastasis in multiple cancer types including pancreatic, glioma, breast, and small cell lung cancer [PMID:579296, PMID:4026390, PMID:15592528, PMID:21530612, PMID:23905012, PMID:32248791]. Its promoter is frequently silenced in tumors by CpG hypermethylation maintained through diverse epigenetic mechanisms including mono-ADP-ribosylation of H3R117 that blocks TET1-mediated demethylation, and lncRNA-mediated recruitment of EZH2, LSD1, or MBD3-NuRD repressor complexes [PMID:12956419, PMID:30651599, PMID:31186379, PMID:35501390]. In glioblastoma, secreted TFPI2 sustains stem cell self-renewal via JNK-STAT3 signaling and engages the receptor CD51 on microglia to drive immunosuppressive STAT6 polarization, while its C-terminal peptide EDC34 exerts direct bactericidal and complement-activating activities [PMID:37067051, PMID:24339780]."},"prefetch_data":{"uniprot":{"accession":"P48307","full_name":"Tissue factor pathway inhibitor 2","aliases":["Placental protein 5","PP5"],"length_aa":235,"mass_kda":26.9,"function":"May play a role in the regulation of plasmin-mediated matrix remodeling. Inhibits trypsin, plasmin, factor VIIa/tissue factor and weakly factor Xa. Has no effect on thrombin","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P48307/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TFPI2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TFPI2","total_profiled":1310},"omim":[{"mim_id":"614489","title":"MICRO RNA 616; MIR616","url":"https://www.omim.org/entry/614489"},{"mim_id":"600033","title":"TISSUE FACTOR PATHWAY INHIBITOR 2; TFPI2","url":"https://www.omim.org/entry/600033"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":899.6}],"url":"https://www.proteinatlas.org/search/TFPI2"},"hgnc":{"alias_symbol":["PP5","TFPI-2","REF1"],"prev_symbol":[]},"alphafold":{"accession":"P48307","domains":[{"cath_id":"4.10.410.10","chopping":"34-88","consensus_level":"high","plddt":97.0756,"start":34,"end":88},{"cath_id":"4.10.410.10","chopping":"95-150","consensus_level":"high","plddt":84.1775,"start":95,"end":150},{"cath_id":"4.10.410.10","chopping":"157-211","consensus_level":"high","plddt":96.4271,"start":157,"end":211}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P48307","model_url":"https://alphafold.ebi.ac.uk/files/AF-P48307-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P48307-F1-predicted_aligned_error_v6.png","plddt_mean":84.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TFPI2","jax_strain_url":"https://www.jax.org/strain/search?query=TFPI2"},"sequence":{"accession":"P48307","fasta_url":"https://rest.uniprot.org/uniprotkb/P48307.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P48307/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P48307"}},"corpus_meta":[{"pmid":"16262633","id":"PMC_16262633","title":"Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation.","date":"2005","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16262633","citation_count":616,"is_preprint":false},{"pmid":"1537340","id":"PMC_1537340","title":"Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1537340","citation_count":613,"is_preprint":false},{"pmid":"11018583","id":"PMC_11018583","title":"Going APE over ref-1.","date":"2000","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/11018583","citation_count":478,"is_preprint":false},{"pmid":"9119221","id":"PMC_9119221","title":"Identification of redox/repair protein Ref-1 as a potent activator of p53.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9119221","citation_count":423,"is_preprint":false},{"pmid":"7506414","id":"PMC_7506414","title":"The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7506414","citation_count":326,"is_preprint":false},{"pmid":"15249685","id":"PMC_15249685","title":"Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15249685","citation_count":319,"is_preprint":false},{"pmid":"15249687","id":"PMC_15249687","title":"The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15249687","citation_count":291,"is_preprint":false},{"pmid":"8355688","id":"PMC_8355688","title":"Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8355688","citation_count":250,"is_preprint":false},{"pmid":"11689443","id":"PMC_11689443","title":"Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11689443","citation_count":249,"is_preprint":false},{"pmid":"15694346","id":"PMC_15694346","title":"A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15694346","citation_count":234,"is_preprint":false},{"pmid":"12357032","id":"PMC_12357032","title":"Selenomethionine regulation of p53 by a ref1-dependent redox mechanism.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12357032","citation_count":215,"is_preprint":false},{"pmid":"12554640","id":"PMC_12554640","title":"Restriction of multiple divergent retroviruses by Lv1 and Ref1.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12554640","citation_count":204,"is_preprint":false},{"pmid":"10523305","id":"PMC_10523305","title":"Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10523305","citation_count":201,"is_preprint":false},{"pmid":"19435926","id":"PMC_19435926","title":"Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19435926","citation_count":197,"is_preprint":false},{"pmid":"15592528","id":"PMC_15592528","title":"Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15592528","citation_count":136,"is_preprint":false},{"pmid":"7961715","id":"PMC_7961715","title":"A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7961715","citation_count":121,"is_preprint":false},{"pmid":"10413457","id":"PMC_10413457","title":"Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10413457","citation_count":108,"is_preprint":false},{"pmid":"579296","id":"PMC_579296","title":"[Isolation and characterization of the placental protein pp5 (author's transl)].","date":"1977","source":"Archiv fur Gynakologie","url":"https://pubmed.ncbi.nlm.nih.gov/579296","citation_count":96,"is_preprint":false},{"pmid":"22474365","id":"PMC_22474365","title":"RNA ligase RtcB splices 3'-phosphate and 5'-OH ends via covalent RtcB-(histidinyl)-GMP and polynucleotide-(3')pp(5')G intermediates.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22474365","citation_count":93,"is_preprint":false},{"pmid":"38781969","id":"PMC_38781969","title":"Peptide REF1 is a local wound signal promoting plant regeneration.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38781969","citation_count":87,"is_preprint":false},{"pmid":"9820167","id":"PMC_9820167","title":"Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers.","date":"1998","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9820167","citation_count":85,"is_preprint":false},{"pmid":"16306589","id":"PMC_16306589","title":"Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16306589","citation_count":84,"is_preprint":false},{"pmid":"9813166","id":"PMC_9813166","title":"Ref-1 controls pax-8 DNA-binding activity.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9813166","citation_count":80,"is_preprint":false},{"pmid":"15942031","id":"PMC_15942031","title":"Analysis of nuclear transport signals in the human apurinic/apyrimidinic endonuclease (APE1/Ref1).","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15942031","citation_count":80,"is_preprint":false},{"pmid":"11420300","id":"PMC_11420300","title":"Overexpression of Ref-1 inhibits hypoxia and tumor necrosis factor-induced endothelial cell apoptosis through nuclear factor-kappab-independent and -dependent pathways.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11420300","citation_count":79,"is_preprint":false},{"pmid":"19586900","id":"PMC_19586900","title":"Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19586900","citation_count":75,"is_preprint":false},{"pmid":"26682532","id":"PMC_26682532","title":"Acute exercise stress promotes Ref1/Nrf2 signalling and increases mitochondrial antioxidant activity in skeletal muscle.","date":"2016","source":"Experimental physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26682532","citation_count":73,"is_preprint":false},{"pmid":"18253812","id":"PMC_18253812","title":"The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer.","date":"2008","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18253812","citation_count":68,"is_preprint":false},{"pmid":"12584341","id":"PMC_12584341","title":"As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12584341","citation_count":68,"is_preprint":false},{"pmid":"23102700","id":"PMC_23102700","title":"The Kelch repeat protein KLHDC10 regulates oxidative stress-induced ASK1 activation by suppressing PP5.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23102700","citation_count":67,"is_preprint":false},{"pmid":"21820798","id":"PMC_21820798","title":"Detection of TFPI2 methylation in the serum of colorectal cancer patients.","date":"2011","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/21820798","citation_count":67,"is_preprint":false},{"pmid":"9405394","id":"PMC_9405394","title":"The serine/threonine phosphatase PP5 interacts with CDC16 and CDC27, two tetratricopeptide repeat-containing subunits of the anaphase-promoting complex.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9405394","citation_count":67,"is_preprint":false},{"pmid":"30442884","id":"PMC_30442884","title":"Long noncoding RNA AC003092.1 promotes temozolomide chemosensitivity through miR-195/TFPI-2 signaling modulation in glioblastoma.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30442884","citation_count":62,"is_preprint":false},{"pmid":"11389770","id":"PMC_11389770","title":"Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling.","date":"2001","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11389770","citation_count":60,"is_preprint":false},{"pmid":"16619485","id":"PMC_16619485","title":"Selenium protection from DNA damage involves a Ref1/p53/Brca1 protein complex.","date":"2006","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16619485","citation_count":59,"is_preprint":false},{"pmid":"9548189","id":"PMC_9548189","title":"Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization.","date":"1998","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/9548189","citation_count":56,"is_preprint":false},{"pmid":"31186379","id":"PMC_31186379","title":"Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31186379","citation_count":56,"is_preprint":false},{"pmid":"37667051","id":"PMC_37667051","title":"Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37667051","citation_count":54,"is_preprint":false},{"pmid":"18280813","id":"PMC_18280813","title":"Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18280813","citation_count":51,"is_preprint":false},{"pmid":"19288010","id":"PMC_19288010","title":"Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma.","date":"2009","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19288010","citation_count":49,"is_preprint":false},{"pmid":"11331294","id":"PMC_11331294","title":"Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11331294","citation_count":49,"is_preprint":false},{"pmid":"23108564","id":"PMC_23108564","title":"Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients.","date":"2012","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23108564","citation_count":47,"is_preprint":false},{"pmid":"25902909","id":"PMC_25902909","title":"Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer.","date":"2015","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25902909","citation_count":46,"is_preprint":false},{"pmid":"18003741","id":"PMC_18003741","title":"Notch-GATA synergy promotes endoderm-specific expression of ref-1 in C. elegans.","date":"2007","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18003741","citation_count":44,"is_preprint":false},{"pmid":"36446791","id":"PMC_36446791","title":"HSP90-CDC37-PP5 forms a structural platform for kinase dephosphorylation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36446791","citation_count":43,"is_preprint":false},{"pmid":"21062455","id":"PMC_21062455","title":"TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21062455","citation_count":43,"is_preprint":false},{"pmid":"22449186","id":"PMC_22449186","title":"Methylation of TFPI-2 is an early event of esophageal carcinogenesis.","date":"2012","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/22449186","citation_count":41,"is_preprint":false},{"pmid":"17602955","id":"PMC_17602955","title":"Redox activation of Ref-1 potentiates cell survival following myocardial ischemia reperfusion injury.","date":"2007","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17602955","citation_count":40,"is_preprint":false},{"pmid":"16051849","id":"PMC_16051849","title":"Capsid processing requirements for abrogation of Fv1 and Ref1 restriction.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16051849","citation_count":40,"is_preprint":false},{"pmid":"22110206","id":"PMC_22110206","title":"Detection of TFPI2 methylation in the serum of gastric cancer patients.","date":"2011","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22110206","citation_count":40,"is_preprint":false},{"pmid":"20335518","id":"PMC_20335518","title":"Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma.","date":"2010","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/20335518","citation_count":39,"is_preprint":false},{"pmid":"24339780","id":"PMC_24339780","title":"The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis.","date":"2013","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/24339780","citation_count":39,"is_preprint":false},{"pmid":"23805888","id":"PMC_23805888","title":"Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.","date":"2013","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/23805888","citation_count":39,"is_preprint":false},{"pmid":"20708786","id":"PMC_20708786","title":"Cervical dysplasia: assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy.","date":"2010","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20708786","citation_count":39,"is_preprint":false},{"pmid":"20113832","id":"PMC_20113832","title":"Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer.","date":"2010","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20113832","citation_count":38,"is_preprint":false},{"pmid":"16549782","id":"PMC_16549782","title":"Rac GTPase signaling through the PP5 protein phosphatase.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16549782","citation_count":37,"is_preprint":false},{"pmid":"33958894","id":"PMC_33958894","title":"SDC2 and TFPI2 Methylation in Stool Samples as an Integrated Biomarker for Early Detection of Colorectal Cancer.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33958894","citation_count":37,"is_preprint":false},{"pmid":"30195776","id":"PMC_30195776","title":"Long Noncoding RNA 00473 Is Involved in Preeclampsia by LSD1 Binding-Regulated TFPI2 Transcription in Trophoblast Cells.","date":"2018","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/30195776","citation_count":37,"is_preprint":false},{"pmid":"20530429","id":"PMC_20530429","title":"Methylation of TFPI2 gene is frequently detected in advanced well-differentiated colorectal cancer.","date":"2010","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20530429","citation_count":36,"is_preprint":false},{"pmid":"28129433","id":"PMC_28129433","title":"Celastrol ameliorates Cd-induced neuronal apoptosis by targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway.","date":"2017","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28129433","citation_count":36,"is_preprint":false},{"pmid":"24327656","id":"PMC_24327656","title":"The molecular chaperone Hsp70 activates protein phosphatase 5 (PP5) by binding the tetratricopeptide repeat (TPR) domain.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24327656","citation_count":36,"is_preprint":false},{"pmid":"37069154","id":"PMC_37069154","title":"Hsp90 provides a platform for kinase dephosphorylation by PP5.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37069154","citation_count":35,"is_preprint":false},{"pmid":"29137404","id":"PMC_29137404","title":"The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29137404","citation_count":35,"is_preprint":false},{"pmid":"32209321","id":"PMC_32209321","title":"Metformin attenuates cadmium-induced neuronal apoptosis in vitro via blocking ROS-dependent PP5/AMPK-JNK signaling pathway.","date":"2020","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32209321","citation_count":35,"is_preprint":false},{"pmid":"31023490","id":"PMC_31023490","title":"P53 supports endothelial barrier function via APE1/Ref1 suppression.","date":"2019","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31023490","citation_count":35,"is_preprint":false},{"pmid":"11737864","id":"PMC_11737864","title":"A novel tetratricopeptide repeat (TPR) containing PP5 serine/threonine protein phosphatase in the malaria parasite, Plasmodium falciparum.","date":"2001","source":"BMC microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11737864","citation_count":35,"is_preprint":false},{"pmid":"32196834","id":"PMC_32196834","title":"TFPI2 and NDRG4 gene promoter methylation analysis in peripheral blood mononuclear cells are novel epigenetic noninvasive biomarkers for colorectal cancer diagnosis.","date":"2020","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32196834","citation_count":34,"is_preprint":false},{"pmid":"21530612","id":"PMC_21530612","title":"Knockdown of TFPI-2 promotes migration and invasion of glioma cells.","date":"2011","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/21530612","citation_count":33,"is_preprint":false},{"pmid":"29142517","id":"PMC_29142517","title":"Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population?","date":"2017","source":"Intestinal research","url":"https://pubmed.ncbi.nlm.nih.gov/29142517","citation_count":33,"is_preprint":false},{"pmid":"15479848","id":"PMC_15479848","title":"Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection.","date":"2004","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/15479848","citation_count":33,"is_preprint":false},{"pmid":"33887608","id":"PMC_33887608","title":"Activation of NRF2 by APE1/REF1 is redox-dependent in Barrett's related esophageal adenocarcinoma cells.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33887608","citation_count":30,"is_preprint":false},{"pmid":"15374638","id":"PMC_15374638","title":"Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15374638","citation_count":30,"is_preprint":false},{"pmid":"24695110","id":"PMC_24695110","title":"Epigenetic silencing of TFPI-2 in canine diffuse large B-cell lymphoma.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24695110","citation_count":28,"is_preprint":false},{"pmid":"12956419","id":"PMC_12956419","title":"Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells.","date":"2003","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12956419","citation_count":28,"is_preprint":false},{"pmid":"10471836","id":"PMC_10471836","title":"Microcystin affinity purification of plant protein phosphatases: PP1C, PP5 and a regulatory A-subunit of PP2A.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10471836","citation_count":27,"is_preprint":false},{"pmid":"17343889","id":"PMC_17343889","title":"Complex determinants within the Moloney murine leukemia virus capsid modulate susceptibility of the virus to Fv1 and Ref1-mediated restriction.","date":"2007","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/17343889","citation_count":26,"is_preprint":false},{"pmid":"7036917","id":"PMC_7036917","title":"Ectopic production of placenta-\"specific\" tissue proteins (PP5 and PP11) by malignant breast tumors.","date":"1981","source":"Archives of gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/7036917","citation_count":26,"is_preprint":false},{"pmid":"16598789","id":"PMC_16598789","title":"Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16598789","citation_count":25,"is_preprint":false},{"pmid":"24333728","id":"PMC_24333728","title":"Protein phosphatase complex PP5/PPP2R3C dephosphorylates P-glycoprotein/ABCB1 and down-regulates the expression and function.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/24333728","citation_count":25,"is_preprint":false},{"pmid":"32248791","id":"PMC_32248791","title":"TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway.","date":"2020","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/32248791","citation_count":24,"is_preprint":false},{"pmid":"32612187","id":"PMC_32612187","title":"Glucocorticoid receptor complexes form cooperatively with the Hsp90 co-chaperones Pp5 and FKBPs.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32612187","citation_count":23,"is_preprint":false},{"pmid":"6975467","id":"PMC_6975467","title":"Detection of placental protein five (PP5) and pregnancy-specific glycoprotein (SP1) in benign and malignant breast disease.","date":"1981","source":"Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6975467","citation_count":23,"is_preprint":false},{"pmid":"35501390","id":"PMC_35501390","title":"MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35501390","citation_count":22,"is_preprint":false},{"pmid":"31486114","id":"PMC_31486114","title":"Vitexin ameliorates preeclampsia phenotypes by inhibiting TFPI-2 and HIF-1α/VEGF in a l-NAME induced rat model.","date":"2019","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/31486114","citation_count":22,"is_preprint":false},{"pmid":"12694636","id":"PMC_12694636","title":"Characterization of Saccharomyces cerevisiae protein Ser/Thr phosphatase T1 and comparison to its mammalian homolog PP5.","date":"2003","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12694636","citation_count":22,"is_preprint":false},{"pmid":"6420205","id":"PMC_6420205","title":"Hyperstimulated human preovulatory follicular fluid contains placental protein 5 (PP5).","date":"1984","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/6420205","citation_count":22,"is_preprint":false},{"pmid":"7644143","id":"PMC_7644143","title":"Ref-1 expression in adult mammalian neurons and astrocytes.","date":"1995","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/7644143","citation_count":22,"is_preprint":false},{"pmid":"35157852","id":"PMC_35157852","title":"TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35157852","citation_count":21,"is_preprint":false},{"pmid":"23905012","id":"PMC_23905012","title":"Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.","date":"2013","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/23905012","citation_count":21,"is_preprint":false},{"pmid":"4026390","id":"PMC_4026390","title":"Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen.","date":"1985","source":"Archives of gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/4026390","citation_count":20,"is_preprint":false},{"pmid":"31036086","id":"PMC_31036086","title":"Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/31036086","citation_count":20,"is_preprint":false},{"pmid":"33658640","id":"PMC_33658640","title":"Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33658640","citation_count":20,"is_preprint":false},{"pmid":"25973077","id":"PMC_25973077","title":"Hypermethylation of TFPI2 correlates with cervical cancer incidence in the Uygur and Han populations of Xinjiang, China.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25973077","citation_count":20,"is_preprint":false},{"pmid":"17352822","id":"PMC_17352822","title":"Identification of a human TFPI-2 splice variant that is upregulated in human tumor tissues.","date":"2007","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17352822","citation_count":20,"is_preprint":false},{"pmid":"20888684","id":"PMC_20888684","title":"Delivery of TFPI-2 using ultrasound with a microbubble agent (SonoVue) inhibits intimal hyperplasia after balloon injury in a rabbit carotid artery model.","date":"2010","source":"Ultrasound in medicine & biology","url":"https://pubmed.ncbi.nlm.nih.gov/20888684","citation_count":20,"is_preprint":false},{"pmid":"23643942","id":"PMC_23643942","title":"Angiopoietin2 enhances doxorubin resistance in HepG2 cells by upregulating survivin and Ref-1 via MSK1 activation.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23643942","citation_count":20,"is_preprint":false},{"pmid":"19524065","id":"PMC_19524065","title":"HIF-1 attenuates Ref-1 expression in endothelial cells: reversal by siRNA and inhibition of geranylgeranylation.","date":"2009","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19524065","citation_count":20,"is_preprint":false},{"pmid":"30651599","id":"PMC_30651599","title":"Mono-ADP-ribosylation of H3R117 traps 5mC hydroxylase TET1 to impair demethylation of tumor suppressor gene TFPI2.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30651599","citation_count":19,"is_preprint":false},{"pmid":"27871841","id":"PMC_27871841","title":"Rubber particle proteins REF1 and SRPP1 interact differently with native lipids extracted from Hevea brasiliensis latex.","date":"2016","source":"Biochimica et biophysica acta. Biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/27871841","citation_count":19,"is_preprint":false},{"pmid":"22391677","id":"PMC_22391677","title":"Effect of acupuncture on hippocampal Ref-1 expression in cerebral multi-infarction rats.","date":"2012","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/22391677","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48610,"output_tokens":4167,"usd":0.104167},"stage2":{"model":"claude-opus-4-6","input_tokens":7460,"output_tokens":3119,"usd":0.172912},"total_usd":0.277079,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking at the corpus, I need to identify papers about TFPI2 (Tissue Factor Pathway Inhibitor 2), a Kunitz-type serine protease inhibitor. Many papers in this corpus are about other genes sharing similar symbols (REF1/APE1, PP5/PPP3, Ref1 retroviral restriction factor, etc.). I need to focus only on TFPI2.\n\nRelevant TFPI2 papers: 14, 15, 18, 33, 36, 37, 38, 46, 47, 52, 53, 58, 68, 74, 77, 80, 83, 84, 86, 88, 89, 90, 94, 95, 98\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1977,\n      \"finding\": \"Placental protein PP5 (later identified as TFPI2) was isolated from human term placenta and characterized as a glycoprotein (MW ~36,600 Da) with serine proteinase-inhibiting activity, capable of inhibiting trypsin and plasmin.\",\n      \"method\": \"Immunoadsorbent purification, ultracentrifugation, electrophoresis, enzymatic inhibition assays\",\n      \"journal\": \"Archiv fur Gynakologie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic inhibition assay with purified protein; single lab, foundational biochemical characterization\",\n      \"pmids\": [\"579296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"PP5/TFPI2 inhibits thrombin-induced coagulation of fibrinogen in a dose-dependent manner, similar to antithrombin III, but without heparin-cofactor activity; PP5 binds heparin but heparin does not accelerate its inhibitory effect.\",\n      \"method\": \"In vitro fibrinogen coagulation assay, heparin-binding assay\",\n      \"journal\": \"Archives of gynecology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay; single lab, single study\",\n      \"pmids\": [\"4026390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PP5/TFPI2 mRNA is specifically expressed in syncytiotrophoblasts of human placenta at all gestational periods examined, with no or little expression in choriocarcinoma cell lines, indicating syncytiotrophoblasts as the principal production site.\",\n      \"method\": \"In situ hybridization, Northern blot analysis\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by in situ hybridization with functional context; single lab\",\n      \"pmids\": [\"9548189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Hypermethylation of the TFPI-2 CpG island promoter silences TFPI-2 transcription in JAR choriocarcinoma cells; in vitro methylation of TFPI-2/luciferase promoter constructs confirmed methylation-dependent transcriptional silencing.\",\n      \"method\": \"5'-aza-2'-deoxycytidine demethylation, luciferase reporter assay, bisulfite genomic sequencing\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter assay with orthogonal methods; single lab\",\n      \"pmids\": [\"12956419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Restored expression of TFPI-2 in pancreatic cancer cells (which have epigenetically silenced TFPI-2) suppresses proliferation, migration, and invasive potential in vitro, establishing TFPI-2 as a functional tumor suppressor through inhibition of extracellular matrix degradation.\",\n      \"method\": \"Stable transfection/re-expression, proliferation assay, migration assay, invasion assay, methylation-specific PCR, microarray\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays with loss-of-function and re-expression; moderate evidence\",\n      \"pmids\": [\"15592528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A novel aberrantly-spliced TFPI-2 (asTFPI-2) transcript lacking 5'-UTR and poly(A)+ tail is expressed 4- to 50-fold more in tumor cells than normal cells, representing an additional mechanism by which tumor cells downregulate functional TFPI-2 protein to enhance extracellular matrix degradation.\",\n      \"method\": \"RT-PCR, 5'- and 3'-RACE, quantitative real-time RT-PCR, nucleotide sequence analysis\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct molecular characterization of splice variant with quantitative expression analysis; single lab\",\n      \"pmids\": [\"17352822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Lentiviral knockdown of TFPI-2 in glioma cell lines significantly increased cell proliferation, migration, and invasion; the anti-invasive properties of TFPI-2 were associated with inhibition of MMP-1 and MMP-2 activity.\",\n      \"method\": \"Lentiviral shRNA knockdown, proliferation assay, migration assay, invasion assay, MMP inhibitor experiments\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with specific phenotypic readout and pathway placement via MMP inhibitors; single lab\",\n      \"pmids\": [\"21530612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The TFPI-2 derived C-terminal peptide EDC34 exerts direct bactericidal effects, boosts activation of the classical complement pathway including formation of antimicrobial C3a, and inhibits bacteria-induced activation of the contact/coagulation system.\",\n      \"method\": \"In vitro bactericidal assay, complement activation assay, mouse infection models (E. coli, P. aeruginosa)\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple in vitro and in vivo mechanistic assays with defined functional readouts; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"24339780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFPI2 is specifically secreted by ovarian clear cell adenocarcinoma (CCA) cell lines and detected at elevated levels in patient sera, identified via mass spectrometry of conditioned media as a biomarker distinguishing CCA from other epithelial ovarian cancer subtypes.\",\n      \"method\": \"Mass spectrometry of conditioned media, RT-PCR, Western blot, ELISA\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — secretome-based identification with orthogonal validation; single lab\",\n      \"pmids\": [\"23805888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"lncRNA AC003092.1 regulates TFPI-2 expression through miR-195 by acting as a competing endogenous RNA (ceRNA), increasing TFPI-2 levels and promoting TMZ-induced apoptosis in glioblastoma cells.\",\n      \"method\": \"qRT-PCR, ceRNA/miRNA luciferase reporter assay, overexpression/knockdown, in vitro and in vivo functional assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ceRNA mechanism with luciferase validation and functional rescue; single lab\",\n      \"pmids\": [\"30442884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"lncRNA linc00473 inhibits TFPI2 transcription in trophoblast cells through binding to LSD1 (lysine-specific demethylase 1), thereby suppressing TFPI2 expression and affecting trophoblast proliferation and apoptosis.\",\n      \"method\": \"RNA-seq, qRT-PCR, RNA immunoprecipitation, siRNA knockdown, overexpression\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA-protein interaction with functional readout; single lab\",\n      \"pmids\": [\"30195776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"lncRNA AGAP2-AS1 interacts with EZH2 and LSD1 and recruits them to the TFPI2 promoter to suppress TFPI2 transcription, promoting glioblastoma cell proliferation and invasion; TFPI2 overexpression reversed AGAP2-AS1-driven oncogenic effects.\",\n      \"method\": \"RNA immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP), overexpression/knockdown, in vitro and in vivo functional assays\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RIP and ChIP with functional rescue; single lab\",\n      \"pmids\": [\"31186379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Mono-ADP-ribosylation of histone H3R117 suppresses TET1 expression and reduces TET1 affinity for the TFPI2 promoter (via H3K9me3 enrichment), thereby impairing demethylation and maintaining hypermethylation of the TFPI2 promoter in colorectal cancer cells.\",\n      \"method\": \"Chromatin immunoprecipitation, bisulfite sequencing, TET1 knockout, H3R117A mutation, ATAC-seq, DNA methylation analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple epigenetic assays with genetic manipulation and direct mechanistic pathway from H3R117 modification to TFPI2 methylation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30651599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TFPI2 suppresses breast cancer cell proliferation, migration, and invasion through inhibiting TWIST1 expression; TWIST1 in turn upregulates integrin α5, and TFPI2 overexpression suppresses tumor growth in vivo via the TWIST1-integrin α5 axis.\",\n      \"method\": \"CCK8 assay, colony formation, wound healing, transwell invasion, Western blot, in vivo xenograft model, immunohistochemistry\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays with pathway placement (TWIST1-integrin α5) and in vivo validation; single lab\",\n      \"pmids\": [\"32248791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MBD3 inhibits TFPI2 transcription via the NuRD complex-mediated deacetylation, reactivating MMP activity and PI3K/AKT signaling, thereby promoting hepatocellular carcinoma growth and metastasis.\",\n      \"method\": \"ChIP, immunoprecipitation, siRNA knockdown, overexpression, in vitro and in vivo functional assays, immunohistochemistry\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and co-IP establishing NuRD complex-mediated epigenetic silencing of TFPI2 with functional consequences; single lab\",\n      \"pmids\": [\"35501390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TFPI2 promotes TGF-β2/Smad signaling-driven endothelial-mesenchymal transition in diabetic nephropathy by interfering with the interaction between SMURF2 and SMAD7, preventing SMAD7-mediated inhibition of the TGF-β2 pathway.\",\n      \"method\": \"Co-immunoprecipitation, AAV-mediated shRNA knockdown in vivo, overexpression in human renal glomerular endothelial cells, high-glucose treatment, EndMT marker analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP establishing protein-protein interaction interference with functional in vitro and in vivo readouts; single lab\",\n      \"pmids\": [\"35157852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TFPI2 promotes glioblastoma stem cell (GSC) self-renewal and tumor growth via activation of the JNK-STAT3 pathway; secreted TFPI2 binds CD51 on microglia to trigger immunosuppressive polarization through STAT6 signaling; inhibition of the TFPI2-CD51-STAT6 axis activates T cells and synergizes with anti-PD1 therapy.\",\n      \"method\": \"Receptor identification (CD51), co-immunoprecipitation/binding assays, genetic knockdown/overexpression, STAT3/STAT6 pathway analysis, mouse GBM models with anti-PD1 combination, flow cytometry\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods identifying receptor (CD51), downstream signaling (JNK-STAT3, STAT6), and functional in vivo validation; single lab but rigorous multi-method approach\",\n      \"pmids\": [\"37067051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFPI-2 overexpression in small cell lung cancer cells decreased MMP expression (particularly MMP-1 and MMP-3) by downregulating phosphorylation of MAPK signaling pathway proteins, and inhibited tumor growth in an orthotopic mouse model.\",\n      \"method\": \"Stable overexpression, in vitro viability/apoptosis/cell cycle assays, MMP expression analysis, Western blot (MAPK phosphorylation), orthotopic mouse model\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression with pathway placement (MAPK-MMP) and in vivo validation; single lab\",\n      \"pmids\": [\"23905012\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFPI2 (Tissue Factor Pathway Inhibitor 2/Placental Protein 5) is a secreted Kunitz-type serine protease inhibitor that inhibits plasmin, trypsin, thrombin, and MMPs to suppress extracellular matrix degradation; its promoter is frequently silenced by CpG hypermethylation (maintained by H3R117 mono-ADP-ribosylation suppressing TET1, or by lncRNAs recruiting EZH2/LSD1/MBD3-NuRD complexes); when expressed, it suppresses tumor invasion via MMP inhibition, activates apoptosis, restrains the JNK-STAT3 stemness pathway in glioblastoma, and its secreted form engages CD51 on microglia to drive immunosuppressive STAT6 signaling, while a C-terminal peptide (EDC34) exerts bactericidal and complement-activating activities.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TFPI2 is a secreted Kunitz-type serine protease inhibitor that functions as a broad regulator of extracellular proteolysis, hemostasis, innate immunity, and tumor suppression. It directly inhibits trypsin, plasmin, and thrombin, and suppresses MMP-1, MMP-2, and MMP-3 activity through MAPK pathway downregulation, thereby restraining extracellular matrix degradation, cell invasion, and metastasis in multiple cancer types including pancreatic, glioma, breast, and small cell lung cancer [PMID:579296, PMID:4026390, PMID:15592528, PMID:21530612, PMID:23905012, PMID:32248791]. Its promoter is frequently silenced in tumors by CpG hypermethylation maintained through diverse epigenetic mechanisms including mono-ADP-ribosylation of H3R117 that blocks TET1-mediated demethylation, and lncRNA-mediated recruitment of EZH2, LSD1, or MBD3-NuRD repressor complexes [PMID:12956419, PMID:30651599, PMID:31186379, PMID:35501390]. In glioblastoma, secreted TFPI2 sustains stem cell self-renewal via JNK-STAT3 signaling and engages the receptor CD51 on microglia to drive immunosuppressive STAT6 polarization, while its C-terminal peptide EDC34 exerts direct bactericidal and complement-activating activities [PMID:37067051, PMID:24339780].\",\n  \"teleology\": [\n    {\n      \"year\": 1977,\n      \"claim\": \"Identification of PP5/TFPI2 as a placental glycoprotein with serine proteinase inhibitor activity established the foundational biochemistry of the protein, answering what molecular activity it encodes.\",\n      \"evidence\": \"Immunoadsorbent purification from human placenta with enzymatic inhibition assays against trypsin and plasmin\",\n      \"pmids\": [\"579296\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitory mechanism (Kunitz domain involvement) not yet defined\", \"No structural characterization\", \"Range of protease targets unknown\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Demonstration that PP5/TFPI2 inhibits thrombin-induced fibrinogen coagulation expanded its substrate repertoire to the coagulation cascade and clarified that, unlike antithrombin III, heparin does not serve as a cofactor for its activity.\",\n      \"evidence\": \"In vitro fibrinogen coagulation assay and heparin-binding assay\",\n      \"pmids\": [\"4026390\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance to hemostasis in vivo not tested\", \"Stoichiometry and kinetics of thrombin inhibition undefined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Localization of TFPI2 mRNA specifically to syncytiotrophoblasts across gestation established the cell type responsible for its placental production and noted its loss in choriocarcinoma, foreshadowing its tumor-suppressive role.\",\n      \"evidence\": \"In situ hybridization and Northern blot on human placental tissue and choriocarcinoma cell lines\",\n      \"pmids\": [\"9548189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of silencing in choriocarcinoma not addressed\", \"Functional role in trophoblast biology not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of CpG island promoter hypermethylation as the mechanism silencing TFPI2 in choriocarcinoma cells provided the first epigenetic explanation for its loss in cancer.\",\n      \"evidence\": \"5-aza-2'-deoxycytidine demethylation, methylated luciferase reporter constructs, bisulfite sequencing in JAR cells\",\n      \"pmids\": [\"12956419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream signals initiating hypermethylation unknown\", \"Generalizability to other tumor types not yet shown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Re-expression of TFPI2 in pancreatic cancer cells suppressed proliferation, migration, and invasion, establishing it as a functional tumor suppressor whose loss enables extracellular matrix degradation.\",\n      \"evidence\": \"Stable transfection/re-expression with proliferation, migration, invasion assays and methylation-specific PCR in pancreatic cancer cell lines\",\n      \"pmids\": [\"15592528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific protease targets mediating ECM degradation not identified in this system\", \"In vivo tumor suppressor activity not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Knockdown of TFPI2 in glioma cells increased proliferation and invasion specifically through enhanced MMP-1 and MMP-2 activity, placing MMP inhibition as the proximal mechanism of its anti-invasive function.\",\n      \"evidence\": \"Lentiviral shRNA knockdown with MMP inhibitor rescue experiments in glioma cell lines\",\n      \"pmids\": [\"21530612\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TFPI2 directly inhibits MMP-1/2 or acts indirectly not resolved\", \"In vivo relevance in glioma not shown in this study\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"TFPI2 overexpression in small cell lung cancer cells revealed that it downregulates MMP-1/3 expression by reducing MAPK pathway phosphorylation and suppresses orthotopic tumor growth, establishing a signaling mechanism upstream of MMP transcription.\",\n      \"evidence\": \"Stable overexpression, Western blot of MAPK phosphorylation, MMP expression analysis, orthotopic mouse model\",\n      \"pmids\": [\"23905012\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How a secreted protease inhibitor alters intracellular MAPK signaling is unclear\", \"Receptor or membrane target mediating this effect not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The C-terminal peptide EDC34 derived from TFPI2 was shown to have direct bactericidal activity, to activate the classical complement pathway generating antimicrobial C3a, and to inhibit bacteria-induced contact activation, revealing an innate immune function distinct from its protease inhibitor activity.\",\n      \"evidence\": \"In vitro bactericidal assays, complement activation assays, mouse infection models with E. coli and P. aeruginosa\",\n      \"pmids\": [\"24339780\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether full-length TFPI2 shares these antimicrobial properties is unclear\", \"Structural basis for complement activation not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple epigenetic silencing mechanisms converging on the TFPI2 promoter were elucidated: mono-ADP-ribosylation of H3R117 maintains promoter hypermethylation by blocking TET1 access, while lncRNAs recruit EZH2, LSD1, and MBD3-NuRD complexes, collectively explaining the diverse routes to TFPI2 loss in cancer.\",\n      \"evidence\": \"ChIP, bisulfite sequencing, TET1 KO, H3R117A mutation, ATAC-seq (colorectal cancer); RIP/ChIP with functional rescue (glioblastoma, trophoblast, hepatocellular carcinoma)\",\n      \"pmids\": [\"30651599\", \"31186379\", \"30195776\", \"35501390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each epigenetic pathway in specific tumor types not compared\", \"Whether these mechanisms operate in normal tissue homeostasis unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"TFPI2 was found to suppress breast cancer invasion through downregulation of TWIST1 and its downstream target integrin α5, adding an EMT-linked transcriptional axis to its tumor-suppressive repertoire.\",\n      \"evidence\": \"Overexpression/knockdown in breast cancer cells, in vivo xenograft, Western blot of TWIST1-integrin α5 axis\",\n      \"pmids\": [\"32248791\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which a secreted protease inhibitor regulates TWIST1 transcription not defined\", \"Direct physical interaction not shown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"TFPI2 was shown to promote TGF-β2/Smad signaling-driven endothelial-mesenchymal transition in diabetic nephropathy by disrupting the SMURF2-SMAD7 interaction, revealing a context-dependent pro-fibrotic role separate from its tumor-suppressive functions.\",\n      \"evidence\": \"Co-immunoprecipitation, AAV-mediated shRNA in vivo, overexpression in renal endothelial cells under high glucose\",\n      \"pmids\": [\"35157852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this SMURF2-SMAD7 disruption occurs via direct binding or protease activity is unknown\", \"Relevance to non-diabetic fibrotic settings not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of CD51 as the microglial receptor for secreted TFPI2 and delineation of dual signaling—JNK-STAT3 in glioblastoma stem cells promoting self-renewal and STAT6 in microglia driving immunosuppression—provided a receptor-to-phenotype mechanism linking TFPI2 to the tumor immune microenvironment.\",\n      \"evidence\": \"Receptor identification (CD51), co-IP/binding assays, STAT3/STAT6 pathway analysis, mouse GBM models with anti-PD1 combination, flow cytometry\",\n      \"pmids\": [\"37067051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD51 engagement requires full-length TFPI2 or specific domains is unknown\", \"Generalizability of TFPI2-CD51-STAT6 axis beyond glioblastoma not tested\", \"Structural basis of TFPI2-CD51 interaction not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single secreted Kunitz-type inhibitor exerts such divergent intracellular signaling effects (MAPK, JNK-STAT3, STAT6, TGF-β/Smad) and whether these depend on its protease-inhibitory activity, direct receptor engagement (e.g., CD51), or distinct protein domains remains an open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Domain-function mapping for signaling versus protease inhibition not performed\", \"No structural model of TFPI2 with receptors or substrates\", \"Relative importance of autocrine versus paracrine roles in the tumor microenvironment unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 6, 17]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 7, 8, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 16, 17]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [4, 6, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CD51\",\n      \"SMURF2\",\n      \"SMAD7\",\n      \"MMP-1\",\n      \"MMP-2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}